Titration News and Research

RSS

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind Corporation today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler.

5 Oct 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

Tight blood sugar control does not benefit pediatric patients undergoing heart surgery

Although some studies have portrayed tight blood sugar control as a potential means of lowering infection rates in critically ill adults, a new study-led by principal investigator Michael Agus, MD, director of the Medicine Critical Care Program at Boston Children's Hospital-found no indication that the approach benefits pediatric patients undergoing heart surgery.

10 Sep 2012

Treatments for peripheral neuropathic pain compared

The first study to compare the 8% capsaicin patch with pregabalin as a treatment for peripheral neuropathic pain begins, with enrolment of the first patient.

31 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Home BP monitoring ‘could help guide dosing, titration’

Researchers report that home blood pressure monitoring provides a reliable indicator of blood pressure control in elderly patients.

19 Jun 2012

Promising preliminary data for axitinib in metastatic kidney cancer

Preliminary study data show that axitinib may be an effective first-line treatment for metastatic renal cell carcinoma, particularly in patients with high therapeutic drug exposure and a rise in blood pressure during the first 2 weeks of treatment, researchers report.

12 Jun 2012

Novel guidelines manage youth maladaptive aggression

Recommendations for the engagement, assessment, treatment, and management of maladaptive aggression in youth have been developed by US experts to improve treatment planning and selection.

6 Jun 2012

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain

An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.

5 Jun 2012

New data from CardioFocus’ HeartLight EAS clinical study on AF

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new worldwide data with its technology was presented during the scientific sessions at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, in Boston, MA last month.

5 Jun 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Hygieia’s DIGS automatically adjusts insulin dosage in patients with diabetes

Newly published results from a clinical study of the Diabetes Insulin Guidance System (DIGS-), under development by Hygieia, Inc., demonstrate DIGS' potential to improve blood glucose control for insulin-using patients with type 2 or type 1 diabetes. DIGS automatically adjusted insulin dosage based on each individual's reported blood glucose results.

10 May 2012

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

PROLOR Biotech, Inc. today reported top-line results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults.

7 May 2012

Xcellerex introduces XDUO Quad single-use mixing system for biomanufacturing

Xcellerex, Inc., a provider of turnkey biomanufacturing solutions, has launched its XDUO Quad single-use mixing system supporting single-use biomanufacturing in upstream and downstream mixing applications and unit operations.

3 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief

For the first time NHS patients in Wales with peripheral nerve pain (known as peripheral neuropathic pain) can be treated with a patch containing capsaicin, which can provide at least 12 weeks pain relief following a single 30- or 60-minute application.

25 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012